Three names recur in the field of incretin-based molecules: Semaglutide, Tirzepatide and Retatrutide. They are often mentioned together, but differ substantially at the scientific level, particularly in their receptor profiles. This comparison considers them strictly scientifically, by the receptors they target and their development status, deliberately without promises of efficacy or effects.
An introductory note on context
Before comparing them, this article considers the three molecules exclusively at the mechanistic and developmental level — the receptors associated with them in scientific literature and their development status.
What this article expressly does not do: make claims about efficacy, effectiveness, use or comparisons of treatment outcomes in humans. Such claims would be neither reliable nor permissible in a research context. This article is for understanding the scientific classification, rather than comparing effects.
Brand names under which some of these active substances are marketed as medicines belong to their respective manufacturers. This article concerns the active substances scientifically, not commercial medicinal products.
The main distinction: receptor profile
The clearest scientific way to categorise these molecules is by receptor profile: at how many and which incretin-related receptors are they described as agonists? Background information on the incretin system is available in the GLP-1 peptide overview.
| Molecule | Receptor profile (as described in research) | Classification |
|---|---|---|
| Semaglutide | GLP-1 receptor | Single agonist |
| Tirzepatide | GLP-1 and GIP receptors | Dual agonist |
| Retatrutide | GLP-1, GIP and glucagon receptors | Triple agonist |
This table is central to the comparison. It shows a clear scientific classification: the number of targeted receptors increases from Semaglutide to Tirzepatide to Retatrutide.
Semaglutide: the single agonist
Semaglutide is described in research as a GLP-1 receptor agonist, primarily targeting one receptor system in the incretin network. It is among the longest and most thoroughly studied molecules in this group and is established as an active substance in approved medicines. Scientifically, it is the “classic” GLP-1 receptor agonist.
Tirzepatide: the dual agonist
Tirzepatide is described in the literature as an agonist at two receptors: GLP-1 and GIP. Compared with Semaglutide, it therefore targets an additional incretin system. This dual targeting is its defining mechanistic feature, making it one level more complex than single agonists.
Retatrutide: the triple agonist
Retatrutide is described in research as a multi-agonist targeting three receptors: GLP-1, GIP and the glucagon receptor. It therefore has the broadest receptor profile in this group. Unlike the other two, it remains a molecule in research and development.
What this comparison shows and leaves open
The classification is clear: the three molecules differ in the number of incretin-related receptors they target — one (Semaglutide), two (Tirzepatide) and three (Retatrutide). This is a clear, understandable scientific classification.
The comparison deliberately leaves open whether targeting more receptors is in any sense “better”. This cannot be inferred from receptor profile alone and would require clinical investigations, beyond the scope of this research overview. A broader receptor profile is a mechanistic property, not a judgement of quality or effects.
Development status at a glance
Development status is another distinction:
- Semaglutide and Tirzepatide: established as active substances in approved medicines and extensively studied clinically
- Retatrutide: in pharmaceutical research and development; in the context presented here, intended exclusively for scientific research and laboratory purposes
This context helps explain the current stage of scientific investigation for each molecule.
Quality in research
The same quality standard applies to all work with research peptides in this field:
- HPLC-verified purity ≥ 99% — find out more in the article on HPLC analysis
- Certificate of Analysis (COA) batch-specific
- Proper lyophilisation and appropriate storage
- Shipping from Germany/EU and transparent origin
AESTX Systems provides research peptides with HPLC-verified purity of ≥ 99% and a COA. In the product overview you will find analysed reference peptides for controlled laboratory conditions, with shipping from Germany.
FAQ — Frequently asked questions about the comparison
What scientifically distinguishes Semaglutide, Tirzepatide and Retatrutide?
Primarily their receptor profiles: Semaglutide is described as a GLP-1 single agonist, Tirzepatide as a GLP-1/GIP dual agonist, and Retatrutide as a GLP-1/GIP/glucagon triple agonist. They differ in the number of incretin-related receptors targeted.
Is a triple agonist “better” than a single agonist?
This cannot be inferred from receptor profile alone. The number of receptors targeted is a mechanistic property, not a judgement of effects or quality. Such comparisons would require clinical research and are outside this overview.
Which of the three are approved as medicines?
Semaglutide and Tirzepatide are established as active substances in approved medicines. Retatrutide remains in research and development. This article considers the active substances scientifically, not commercial products.
Does this article make claims about efficacy?
No. The comparison is deliberately limited to receptor profile and development status. Claims about efficacy, effectiveness or human applications are outside this research overview.
Conclusion
Semaglutide, Tirzepatide and Retatrutide can be most clearly categorised scientifically by receptor profile: one, two or three incretin-related receptors targeted. This classification is clear and understandable but deliberately says nothing about efficacy. Keeping mechanistic description separate from judgements of effects distinguishes a reliable scientific assessment from impermissible promises. Research in this field requires the same priority as elsewhere: reliable, analysed material.
Further research articles:
- GLP-1 peptides in research: The incretin system explained
- Retatrutide: Research overview of the peptide
- Peptide purity: HPLC analysis explained
- What are peptides? A simple guide to the basics
Disclaimer: All substances mentioned on this page are offered exclusively for scientific research and laboratory purposes. They are not medicines, foods or cosmetics and are not intended for human or animal use or for diagnosing or treating diseases. Mentioned brand names belong to their respective owners; no affiliation or endorsement is implied. The information on this page does not replace medical advice. Always consult a qualified doctor about health concerns.